Trends in oral drug bioavailability following bariatric surgery: Examining the variable extent of impact on exposure of different drug classes

British Journal of Clinical Pharmacology

Volumn 74, Issue 5, 2012, Pages 774-787

  Darwich, Adam S ^a   Henderson, Kathryn ^a   Burgin, Angela ^b,c   Ward, Nicola ^d   Whittam, Janet ^b,c   Ammori, Basil J ^b,c   Ashcroft, Darren M ^b   Rostami Hodjegan, Amin ^a,e  

^a School of Pharmacy and Pharmaceutical Sciences   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^d LEICESTER ROYAL INFIRMARY   (United Kingdom)

^e CERTARA UK LIMITED   (United Kingdom)

Author keywords

Bariatric surgery; Biopharmaceutics classification system; CYP2C; CYP2D6; CYP3A; Oral bioavailability

Indexed keywords

AMPICILLIN; ATORVASTATIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; LEVONORGESTREL; METFORMIN; NORETHISTERONE; PARACETAMOL; PENICILLIN V; PHENAZONE; PHENYTOIN; PROPYLTHIOURACIL; PROTON PUMP INHIBITOR; RANITIDINE; RAPAMYCIN; SERTRALINE; SULFAFURAZOLE;

ARTICLE; BARIATRIC SURGERY; CLINICAL PRACTICE; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; MEDICAL AUDIT; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; ADULT; BARIATRIC SURGERY; BIOLOGICAL AVAILABILITY; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SOLUBILITY; YOUNG ADULT;

EID: 84862235432     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04284.x     Document Type: Article

References (121)

1. Picot J, Jones J, Colquitt JL, Gospodarevskaya E, Loveman E, Baxter L, Clegg AJ. The clinical effectiveness and cost effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 2009; 13: 1-358.
2. Obesity and Overweight. Fact Sheet 311. Geneva: World Health Organisation, 2006. Available at http://www.who.int/mediacentre/factsheets/fs311/en/ (last accessed 8 November 2011).
3. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-41.
4. Sassi F. Obesity and the Economics of Prevention: Fit Not Fat - United Kingdom (England) Key Facts. Paris: Organisation for Economic Co-operation and Development, London, 2011.
5. O'Neill P. Office of Health Economics, UK. Shedding the Pounds: Obesity Management, NICE Guidance and Bariatric Surgery in England. London: Office of Health Economics, 2010.
6. Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide 2008. Obes Surg 2009; 19: 1605-11.
7. The NHS Information Centre. Lifestyle Statistics. Statistics on Obesity, Physical Activity and Diet: England, 2010, First Edition. Leeds: The Health and Social Care Information Centre, 2010.
8. National Institute of Diabetes and Digestive and Kidney Diseases. Bariatric Surgery for Severe Obesity. Bethesda, MD: National Institute of Health, 2010.
9. Singh D, Laya AS, Clarkston WK, Allen MJ. Jejunoileal bypass: a surgery of the past and a review of its complications. World J Gastroenterol 2009; 15: 2277-9.
10. Griffen WO Jr, Young VL, Stevenson CC. A prospective comparison of gastric and jejunoileal bypass procedures for morbid obesity. Ann Surg 1977; 186: 500-9.
11. Elder KA, Wolfe BM. Bariatric surgery: a review of procedures and outcomes. Gastroenterology 2007; 132: 2253-71.
12. Schneider BE, Mun EC. Surgical management of morbid obesity. Diabetes Care 2005; 28: 475-80.
13. Lee CM, Cirangle PT, Jossart GH. Vertical gastrectomy for morbid obesity in 216 patients: report of two-year results. Surg Endosc 2007; 21: 1810-6.
14. Hess DS, Hess DW. Biliopancreatic diversion with a duodenal switch. Obes Surg 1998; 8: 267-82.
15. Spak E, Bjorklund P, Helander HF, Vieth M, Olbers T, Casselbrant A, Lonroth H, Fandriks L. Changes in the mucosa of the Roux-limb after gastric bypass surgery. Histopathology 2010; 57: 680-8.
16. DeMaria EJ, Sugerman HJ, Kellum JM, Meador JG, Wolfe LG. Results of 281 consecutive total laparoscopic Roux-en-Y gastric bypasses to treat morbid obesity. Ann Surg 2002; 235: 640-5. discussion 45-7.
17. Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Roux-en-Y- 500 patients: technique and results, with 3-60 month follow-up. Obes Surg 2000; 10: 233-9.
18. Rowland M, Tozer TN. In: Clinical Pharmacokinetics: Concepts and Applications, 2nd edn. Philadelphia, PA: Lea & Febiger, 1989.
19. Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, Tucker G. Population-based mechanistic prediction of oral drug absorption. AAPS J 2009; 11: 225-37.
20. Higaki K, Choe SY, Lobenberg R, Welage LS, Amidon GL. Mechanistic understanding of time-dependent oral absorption based on gastric motor activity in humans. Eur J Pharm Biopharm 2008; 70: 313-25.
21. Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, Watkins PB. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994; 4: 247-59.
22. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. The human intestinal cytochrome P450 'pie'. Drug Metab Dispos 2006; 34: 880-6.
23. Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 2001; 33: 273-97.
24. Riches Z, Stanley EL, Bloomer JC, Coughtrie MW. Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT 'pie'. Drug Metab Dispos 2009; 37: 2255-61.
25. Peters WH, Roelofs HM, Nagengast FM, van Tongeren JH. Human intestinal glutathione S-transferases. Biochem J 1989; 257: 471-6.
26. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283: 1552-62.
27. Benet LZ, Cummins CL. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev 2001; 50: (Suppl. 1): S3-11.
28. Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 2003; 20: 1595-9.
29. FDA, Center for Drug Evaluation and Research. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on A Biopharmaceutics Classification System. Rockville, MD: U.S. Department of Health and Human Services, 2000.
30. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-20.
31. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. Chichester: John Wiley & Sons, Ltd, 2009.
32. Fuller AK, Tingle D, DeVane CL, Scott JA, Stewart RB. Haloperidol pharmacokinetics following gastric bypass surgery. J Clin Psychopharmacol 1986; 6: 376-8.
33. Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant 2008; 22: 281-91.
34. Terry SI, Gould JC, McManus JP, Prescott LF. Absorption of penicillin and paracetamol after small intestinal bypass surgery. Eur J Clin Pharmacol 1982; 23: 245-8.
35. Liu H, Artz AS. Reduction of imatinib absorption after gastric bypass surgery. Leuk Lymphoma 2011; 52: 310-3.
36. Skottheim IB, Jakobsen GS, Stormark K, Christensen H, Hjelmesaeth J, Jenssen T, Asberg A, Sandbu R. Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch. Clin Pharmacol Ther 2010; 87: 699-705.
37. Skottheim IB, Stormark K, Christensen H, Jakobsen GS, Hjelmesaeth J, Jenssen T, Reubsaet JL, Sandbu R, Asberg A. Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin Pharmacol Ther 2009; 86: 311-8.
38. Gerson CD, Lowe EH, Lindenbaum J. Bioavailability of digoxin tablets in patients with gastrointestinal dysfunction. Am J Med 1980; 69: 43-9.
39. Marcus FI, Quinn EJ, Horton H, Jacobs S, Pippin S, Stafford M, Zukoski C. The effect of jejunoileal bypass on the pharmacokinetics of digoxin in man. Circulation 1977; 55: 537-41.
40. Cossu ML, Caccia S, Coppola M, Fais E, Ruggiu M, Fracasso C, Nacca A, Noya G. Orally administered ranitidine plasma concentrations before and after biliopancreatic diversion in morbidly obese patients. Obes Surg 1999; 9: 36-9.
41. Adami GF, Gandolfo P, Esposito M, Scopinaro N. Orally-administered serum ranitidine concentration after biliopancreatic diversion for obesity. Obes Surg 1991; 1: 293-94.
42. Malone M, Alger-Mayer SA. Medication use patterns after gastric bypass surgery for weight management. Ann Pharmacother 2005; 39: 637-42.
43. Ponsky TA, Brody F, Pucci E. Alterations in gastrointestinal physiology after Roux-en-Y gastric bypass. J Am Coll Surg 2005; 201: 125-31.
44. Buchwald H, Williams SE. Bariatric surgery worldwide 2003. Obes Surg 2004; 14: 1157-64.
45. Horowitz M, Cook DJ, Collins PJ, Harding PE, Hooper MJ, Walsh JF, Shearman DJ. Measurement of gastric emptying after gastric bypass surgery using radionuclides. Br J Surg 1982; 69: 655-7.
46. Braghetto I, Davanzo C, Korn O, Csendes A, Valladares H, Herrera E, Gonzalez P, Papapietro K. Scintigraphic evaluation of gastric emptying in obese patients submitted to sleeve gastrectomy compared to normal subjects. Obes Surg 2009; 19: 1515-21.
47. Smith CD, Herkes SB, Behrns KE, Fairbanks VF, Kelly KA, Sarr MG. Gastric acid secretion and vitamin B12 absorption after vertical Roux-en-Y gastric bypass for morbid obesity. Ann Surg 1993; 218: 91-6.
48. Behrns KE, Smith CD, Sarr MG. Prospective evaluation of gastric acid secretion and cobalamin absorption following gastric bypass for clinically severe obesity. Dig Dis Sci 1994; 39: 315-20.
49. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997; 32: 403-25.
50. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35: 1096-107.
51. van de Merbel NC, Wilkens G, Fowles S, Oosterhuis B, Jonkman JHG. LC phases improve, but not all assays do: metformin bioanalysis revisited. Chromatographia 1998; 47: 542-46.
52. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004; 1: 85-96.
53. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981; 12: 235-46.
54. Proctor WR, Bourdet DL, Thakker DR. Mechanisms underlying saturable intestinal absorption of metformin. Drug Metab Dispos 2008; 36: 1650-8.
55. Padwal RS, Gabr RQ, Sharma AM, Langkaas LA, Birch DW, Karmali S, Brocks DR. Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care 2011; 34: 1295-300.
56. Cole M, Kenig MD, Hewitt VA. Metabolism of penicillins to penicilloic acids and 6-aminopenicillanic acid in man and its significance in assessing penicillin absorption. Antimicrob Agents Chemother 1973; 3: 463-8.
57. Chenhsu RY, Wu Y, Katz D, Rayhill S. Dose-adjusted cyclosporine c2 in a patient with jejunoileal bypass as compared to seven other liver transplant recipients. Ther Drug Monit 2003; 25: 665-70.
58. Knight GC, Macris MP, Peric M, Duncan JM, Frazier OH, Cooley DA. Cyclosporine A pharmacokinetics in a cardiac allograft recipient with a jejuno-ileal bypass. Transplant Proc 1988; 20: 351-5.
59. Ablassmaier B, Klaua S, Jacobi CA, Muller JM. Laparoscopic gastric banding after heart transplantation. Obes Surg 2002; 12: 412-5.
60. Chemical C. Product Information - Imatinib (Mesylate). Ann Arbor, MI: Cayman Chemical Company, 2010.
61. FDA. Drugs@FDA: FDA Approved Drug Products. Rockville, MD: U.S. Department of Health and Human Services, 2010.
62. Ni J, Ouyang H, Aiello M, Seto C, Borbridge L, Sakuma T, Ellis R, Welty D, Acheampong A. Microdosing assessment to evaluate pharmacokinetics and drug metabolism in rats using liquid chromatography-tandem mass spectrometry. Pharm Res 2008; 25: 1572-82.
63. Ashiru DA, Patel R, Basit AW. Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. Pharm Res 2008; 25: 2327-33.
64. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004; 58: 265-78.
65. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005; 22: 11-23.
66. Oie S, Gambertoglio JG, Fleckenstein L. Comparison of the disposition of total and unbound sulfisoxazole after single and multiple dosing. J Pharmacokinet Biopharm 1982; 10: 157-72.
67. Kaplan SA, Weinfeld RE, Abruzzo CW, Lewis M. Pharmacokinetic profile of sulfisoxazole following intravenous, intramuscular, and oral administration to man. J Pharm Sci 1972; 61: 773-8.
68. Yalkowsky SH, He Y. Handbook of Aqueous Solubility Data. Boca Raton, FL: CRC Press, 2003.
69. Lennernas H, Gjellan K, Hallgren R, Graffner C. The influence of caprate on rectal absorption of phenoxymethylpenicillin: experience from an in-vivo perfusion in humans. J Pharm Pharmacol 2002; 54: 499-508.
70. Stewart BH, Chan OH, Lu RH, Reyner EL, Schmid HL, Hamilton HW, Steinbaugh BA, Taylor MD. Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans. Pharm Res 1995; 12: 693-9.
71. Bock U, Kottke T, Gindorf C, Haltner E. Validation of the Caco-2 cell monolayer system for determining the permeability of drug substances according to the Biopharmaceutics Classification System (BCS). Saarbrucken: Across Barriers, 2003: 1-7. Available at http://www.acrossbarriers.de/uploads/media/FCT02-I-0305_BCS_01.pdf (last accessed 8 November 2011).
72. Dressman JB, Amidon GL, Fleisher D. Absorption potential: estimating the fraction absorbed for orally administered compounds. J Pharm Sci 1985; 74: 588-9.
73. Garekani HA, Sadeghi F, Ghazi A. Increasing the aqueous solubility of acetaminophen in the presence of polyvinylpyrrolidone and investigation of the mechanisms involved. Drug Dev Ind Pharm 2003; 29: 173-9.
74. Joint Formulary Committee. British National Formulary, Sixty-Second edn. London: BMJ Group and Pharmaceutical Press, 2011.
75. Crowe A, Lemaire M. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res 1998; 15: 1666-72.
76. Tamura S, Ohike A, Ibuki R, Amidon GL, Yamashita S. Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci 2002; 91: 719-29.
77. Tavelin S, Milovic V, Ocklind G, Olsson S, Artursson P. A conditionally immortalized epithelial cell line for studies of intestinal drug transport. J Pharmacol Exp Ther 1999; 290: 1212-21.
78. Petan JA, Undre N, First MR, Saito K, Ohara T, Iwabe O, Mimura H, Suzuki M, Kitamura S. Physiochemical properties of generic formulations of tacrolimus in Mexico. Transplant Proc 2008; 40: 1439-42.
79. Kearney AS, Crawford LF, Mehta SC, Radebaugh GW. The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981. Pharm Res 1993; 10: 1461-5.
80. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003; 42: 1141-60.
81. Song NN, Li QS, Liu CX. Intestinal permeability of metformin using single-pass intestinal perfusion in rats. World J Gastroenterol 2006; 12: 4064-70.
82. Kampmann J, Skovsted L. The pharmacokinetics of propylthiouracil. Acta Pharmacol Toxicol (Copenh) 1974; 35: 361-9.
83. Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 1999; 115: 12-8.
84. Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Barends DM. Biowaiver monographs for immediate release solid oral dosage forms: ethambutol dihydrochloride. J Pharm Sci 2008; 97: 1350-60.
85. Nelson E, Powell JR, Conrad K, Likes K, Byers J, Baker S, Perrier D. Phenobarbital pharmacokinetics and bioavailability in adults. J Clin Pharmacol 1982; 22: 141-8.
86. Patel IH, Levy RH, Bauer TG. Pharmacokinetic properties of ethosuximide in monkeys. I. Single-dose intravenous and oral administration. Epilepsia 1975; 16: 705-16.
87. Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U, Seiberling M. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004; 53: 102-6.
88. Wenzel KW, Kirschsieper HE. Aspects of the absorption of oral L-thyroxine in normal man. Metabolism 1977; 26: 1-8.
89. NCBI PubChem Public Chemical Database. National Center of Biotechnology Information. Bethesda, MD: National Institute of Health, 2011. Available at http://www.ncbi.nlm.nih.gov/pubmed/ (last accessed 8 November 2011).
90. Kampmann JP, Klein H, Lumholtz B, Molholm Hansen JE. Ampicillin and propylthiouracil pharmacokinetics in intestinal bypass patients followed up to a year after operation. Clin Pharmacokinet 1984; 9: 168-76.
91. Andreasen PB, Dano P, Kirk H, Greisen G. Drug absorption and hepatic drug metabolism in patients with different types of intestinal shunt operation for obesity. A study with phenazone. Scand J Gastroenterol 1977; 12: 531-5.
92. Prince RA, Pincheira JC, Mason EE, Printen KJ. Influence of bariatric surgery on erythromycin absorption. J Clin Pharmacol 1984; 24: 523-7.
93. Garrett ER, Suverkrup RS, Eberst K, Yost RL, O'Leary JP. Surgically affected sulfisoxazole pharmacokinetics in the morbidly obese. Biopharm Drug Dispos 1981; 2: 329-65.
94. Victor A, Odlind V, Kral JG. Oral contraceptive absorption and sex hormone binding globulins in obese women: effects of jejunoileal bypass. Gastroenterol Clin North Am 1987; 16: 483-91.
95. Genentech. Cellcept Prescribing Information. San Fransisco, CA: Genentech USA Inc, 2010.
96. Mathew TH, Van Buren C, Kahan BD, Butt K, Hariharan S, Zimmerman JJ. A comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection. J Clin Pharmacol 2006; 46: 76-87.
97. Brattstrom C, Sawe J, Jansson B, Lonnebo A, Nordin J, Zimmerman JJ, Burke JT, Groth CG. Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers. Ther Drug Monit 2000; 22: 537-44.
98. Backman L, Beerman B, Groschinsky-Grind M, Hallberg D. Malabsorption of hydrochlorothiazide following intestinal shunt surgery. Clin Pharmacokinet 1979; 4: 63-8.
99. Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977; 12: 297-303.
100. Roerig JL, Steffen K, Zimmerman C, Mitchell JE, Crosby RD, Cao L. Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. Surg Obes Relat Dis 2012; 8: 62-6.
101. Kennedy MC, Wade DN. Phenytoin absorption in patients with ileojejunal bypass. Br J Clin Pharmacol 1979; 7: 515-8.
102. Dowell JA, Stogniew M, Krause D, Henkel T, Damle B. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J Clin Pharmacol 2007; 47: 305-14.
103. Andersen AN, Lebech PE, Sorensen TI, Borggaard B. Sex hormone levels and intestinal absorption of estradiol and D-norgestrel in women following bypass surgery for morbid obesity. Int J Obes 1982; 6: 91-6.
104. Gerrits EG, Ceulemans R, van Hee R, Hendrickx L, Totte E. Contraceptive treatment after biliopancreatic diversion needs consensus. Obes Surg 2003; 13: 378-82.
105. Griffiths TM, Thomas P, Campbell IA. Antituberculosis drug levels after jejunoileal bypass. Br J Dis Chest 1982; 76: 286-9.
106. Harris JO, Wasson KR. Tuberculosis after intestinal bypass operation for obesity. Ann Intern Med 1977; 86: 115-6.
107. Bruce RM, Wise L. Tuberculosis after jejunoileal bypass for obesity. Ann Intern Med 1977; 87: 574-6.
108. Pickleman JR, Evans LS, Kane JM, Freeark RJ. Tuberculosis after jejunoileal bypass for obesity. JAMA 1975; 234: 744.
109. Werbin N. Tuberculosis after jejuno-ileal bypass for morbid obesity. Postgrad Med J 1981; 57: 252-3.
110. Polk RE, Tenenbaum M, Kline B. Isoniazid and ethambutol absorption with jejunoileal bypass. Ann Intern Med 1978; 89: 430-1.
111. Magee SR, Shih G, Hume A. Malabsorption of oral antibiotics in pregnancy after gastric bypass surgery. J Am Board Fam Med 2007; 20: 310-3.
112. Kelley M, Jain A, Kashyap R, Orloff M, Abt P, Wrobble K, Venkataramanan R, Bozorgzadeh A. Change in oral absorption of tacrolimus in a liver transplant recipient after reversal of jejunoileal bypass: case report. Transplant Proc 2005; 37: 3165-7.
113. Pournaras DJ, Footitt D, Mahon D, Welbourn R. Reduced phenytoin levels in an epileptic patient following Roux-En-Y gastric bypass for obesity. Obes Surg 2011; 21: 684-5.
114. Peterson DI, Zweig RW. Absorption of anticonvulsants after jejunoileal bypass. Bull Los Angeles Neurol Soc 1974; 39: 51-5.
115. Peterson DI. Phenytoin absorption following jejunoileal bypass. Bull Clin Neurosci 1983; 48: 148-9.
116. Wills SM, Zekman R, Bestul D, Kuwajerwala N, Decker D. Tamoxifen malabsorption after Roux-en-Y gastric bypass surgery: case series and review of the literature. Pharmacotherapy 2011; 30: 217.
117. Park DM, Shah DD, Egorin MJ, Beumer JH. Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery. J Neurooncol 2009; 93: 279-83.
118. Boffito M, Lucchini A, Maiello A, Dal Conte I, Hoggard PG, Back DJ, Di Perri G. Lopinavir/ritonavir absorption in a gastrectomized patient. AIDS 2003; 17: 136-7.
119. Topliss DJ, Wright JA, Volpe R. Increased requirement for thyroid hormone after a jejunoileal bypass operation. Can Med Assoc J 1980; 123: 765-6.
120. Azizi F, Belur R, Albano J. Malabsorption of thyroid hormones after jejunoileal bypass for obesity. Ann Intern Med 1979; 90: 941-2.
121. Bevan JS, Munro JF. Thyroxine malabsorption following intestinal bypass surgery. Int J Obes 1986; 10: 245-6.